Phio Pharmaceuticals Corp Asset Resilience Ratio
Phio Pharmaceuticals Corp asset resilience ratio. Phio Pharmaceuticals Corp (PHIO) has an Asset Resilience Ratio of 1.31% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Phio Pharmaceuticals Corp to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Phio Pharmaceuticals Corp (2012–2017)
Asset resilience ratio of Phio Pharmaceuticals Corp from 2012 to 2017. This chart shows how Phio Pharmaceuticals Corp's Asset Resilience Ratio has changed over time. Read PHIO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Phio Pharmaceuticals Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PHIO asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.00K | 1.31% |
| Total Liquid Assets | $50.00K | 1.31% |
Asset Resilience Insights
- Limited Liquidity: Phio Pharmaceuticals Corp maintains only 1.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Phio Pharmaceuticals Corp Industry Peers by Asset Resilience Ratio
Compare Phio Pharmaceuticals Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Phio Pharmaceuticals Corp Asset Resilience Ratio by Year (2012–2017)
Phio Pharmaceuticals Corp asset resilience ratio by year from 2012 to 2017. The table below shows the annual Asset Resilience Ratio data for Phio Pharmaceuticals Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 1.22% | $50.00K | $4.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $13.40 Million | -- |
| 2015-12-31 | 49.29% | $5.50 Million | $11.16 Million | +48.74pp |
| 2014-12-31 | 0.54% | $50.00K | $9.19 Million | -19.54pp |
| 2013-12-31 | 20.08% | $3.00 Million | $14.94 Million | +19.14pp |
| 2012-12-31 | 0.95% | $53.00K | $5.59 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more